US Stock MarketDetailed Quotes
LQDA Liquidia
- 12.060
- -0.420-3.37%
Close May 10 16:00 ET
- 12.500
- +0.440+3.65%
Post 19:24 ET
921.18MMarket Cap-9966P/E (TTM)
12.520High11.990Low637.05KVolume12.350Open12.480Pre Close7.71MTurnover1.27%Turnover RatioLossP/E (Static)76.38MShares16.99052wk High19.48P/B605.98MFloat Cap5.71052wk Low--Dividend TTM50.25MShs Float38.460Historical High--Div YieldTTM4.24%Amplitude2.250Historical Low12.108Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Liquidia Stock Forum
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US)$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US)$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US)$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US)$ : CRL 4/22 🙁
⚠...
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...
$Vanda Pharmaceuticals(VNDA.US)$ $Legend Biotech(LEGN.US)$ $Supernus Pharmaceuticals(SUPN.US)$ $ImmunityBio(IBRX.US)$ $Aquestive Therapeutics(AQST.US)$ $X4 Pharmaceuticals(XFOR.US)$ $Liquidia(LQDA.US)$ $Neurocrine Biosciences(NBIX.US)$ $Moderna(MRNA.US)$ $Day One Biopharmaceuticals(DAWN.US)$
...
$Eyenovia(EYEN.US)$ $Vanda Pharmaceuticals(VNDA.US)$ $Mirum Pharmaceuticals(MIRM.US)$ $Madrigal Pharmaceuticals(MDGL.US)$ $Geron(GERN.US)$ $Bristol-Myers Squibb(BMY.US)$ $2seventy bio(TSVT.US)$ $Legend Biotech(LEGN.US)$ $OptiNose(OPTN.US)$ $Orchard Therapeutics(ORTX.US)$ $Merck & Co(MRK.US)$ $Akebia Therapeutics(AKBA.US)$ $AstraZeneca(AZN.US)$ $Liquidia(LQDA.US)$ $Esperion Therapeutics(ESPR.US)$ $Regeneron Pharmaceuticals(REGN.US)$ $BeiGene(BGNE.US)$
$Heron Therapeutics(HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US)$ & $Regeneron Pharmaceuticals(REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
⇒ NDA review remains ongoing
⇒ Confirms the process for adding the PH-ILD
indication as an amendment
⇒ Couldn't issue an action letter in time
📍• YUTREPIA
⇒ PDUFA goal date: 1/24/24
⇒ NDA
⇒ PH-ILD
Moomoo 24/7· 2 mins ago
$Heron Therapeutics(HRTX.US)$ : 🤔
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
📌Next week’s PDUFAs:
$Sanofi(SNY.US)$ & $Regeneron Pharmaceuticals(REGN.US)$ : 🤔
⇒ Dupixent
⇒ Eosinophilic Esophagitis (pedia)
⇒ sBLA
⇒ PDUFA: 01/31/24
No comment yet